Traumatic Brain Injury and Neuroinflammation: Review of the Main Biomarkers
https://doi.org/10.29413/ABS.2020-5.5.8
Abstract
Traumatic brain injury is one of the main causes of both acute and long-term morbidity that concern that affects individuals in all demographics. The processes that occur during traumatic brain injury and neuroinflammation cannot be fully explained in most clinical and preclinical researches.
Neuroinflammation is a very complex interaction between the cells of the innate and adaptive immune systems. The development of reactions of the innate immune system occurs under the influence of various signals that are released from damaged cells and tissues. This leads to the activation of neutrophils, microglia and astrocytes, the release of complement, as well as the release of histamine by mast cells.
Subsequently, activation of an adaptive immune response leads to the development of later effects of neuroinflammation. The topic of biomarkers in traumatic brain injury is extensive and rapidly developing. We presented an overview of the most common and well-studied biomarkers in the literature regarding head injury in humans and their role in predicting the outcome in traumatic brain injury.
Among the presented biomarkers, the most specific for traumatic brain injury are interleukins-6, -8, -10 and matrix metalloproteinases. We can use interleukin-6 to predict the outcome and risk of complications of traumatic brain injury. The concentration of interleukin-8 shows the relationship of the biomarker with mortality. We can use interleukin-10 to confirm the results of computed tomography in traumatic brain injury. Matrix metalloproteinases present the degree of violation of the blood-brain barrier and brain dysfunction. Other indicators need a more complete study to clarify their role in this pathology. Of course, for a more reliable conclusion about the patient›s condition, it is preferable to use the data of several biomarkers at the same time.
Neuroinflammation is a very complex interaction between the cells of the innate and adaptive immune systems. The development of reactions of the innate immune system occurs under the influence of various signals that are released from damaged cells and tissues. This leads to the activation of neutrophils, microglia and astrocytes, the release of complement, as well as the release of histamine by mast cells.
Subsequently, activation of an adaptive immune response leads to the development of later effects of neuroinflammation. The topic of biomarkers in traumatic brain injury is extensive and rapidly developing. We presented an overview of the most common and well-studied biomarkers in the literature regarding head injury in humans and their role in predicting the outcome in traumatic brain injury.
Among the presented biomarkers, the most specific for traumatic brain injury are interleukins-6, -8, -10 and matrix metalloproteinases. We can use interleukin-6 to predict the outcome and risk of complications of traumatic brain injury. The concentration of interleukin-8 shows the relationship of the biomarker with mortality. We can use interleukin-10 to confirm the results of computed tomography in traumatic brain injury. Matrix metalloproteinases present the degree of violation of the blood-brain barrier and brain dysfunction. Other indicators need a more complete study to clarify their role in this pathology. Of course, for a more reliable conclusion about the patient›s condition, it is preferable to use the data of several biomarkers at the same time.
About the Authors
A. I. Zudova
Institute of Natural Sciences and Mathematics, Ural Federal University named after the first President of Russia B.N. Yeltsin;
Institute of Immunology and Physiology of the Ural Branch of the Russian Academy of Sciences
Russian Federation
Student
ul. Mira 19, Yekaterinburg 620002, Russian Federation ul. Pervomayskaya 106, 620046, Yekaterinburg Russia, Russian Federation
Russian Federation
Student
ul. Mira 19, Yekaterinburg 620002, Russian Federation ul. Pervomayskaya 106, 620046, Yekaterinburg Russia, Russian Federation
A. G. Sukhorosova
Institute of Natural Sciences and Mathematics, Ural Federal University named after the first President of Russia B.N. Yeltsin;
Institute of Immunology and Physiology of the Ural Branch of the Russian Academy of Sciences
Russian Federation
Student
ul. Mira 19, Yekaterinburg 620002, Russian Federation ul. Pervomayskaya 106, 620046, Yekaterinburg Russia, Russian Federation
Russian Federation
Student
ul. Mira 19, Yekaterinburg 620002, Russian Federation ul. Pervomayskaya 106, 620046, Yekaterinburg Russia, Russian Federation
L. V. Solomatina
Institute of Natural Sciences and Mathematics, Ural Federal University named after the first President of Russia B.N. Yeltsin;
Institute of Immunology and Physiology of the Ural Branch of the Russian Academy of Sciences
Russian Federation
Cand. Sc. (Med.), Senior Lecturer of the Department of Medical Biochemistry and Biophysics
ul. Mira 19, Yekaterinburg 620002, Russian Federation ul. Pervomayskaya 106, 620046, Yekaterinburg Russia, Russian Federation
Russian Federation
Cand. Sc. (Med.), Senior Lecturer of the Department of Medical Biochemistry and Biophysics
ul. Mira 19, Yekaterinburg 620002, Russian Federation ul. Pervomayskaya 106, 620046, Yekaterinburg Russia, Russian Federation
References
1. Menon DK, Schwab K, Wright DW, Maas AI, et al. Position statement: definition of traumatic brain injury. Arch Phys Med Rehabil. 2010; 91(11): 1637-1640. doi: 10.1016/j.apmr.2010.05.017
2. Yilmaz C, Karali K, Fodelianaki G, Gravanis A, Chavakis T, Charalampopoulos I, et al. Neurosteroids as regulators of neuroinflammation. Front Neuroendocrinol. 2019; 55: 100788. doi: 10.1016/j.yfrne.2019.100788
3. Ministry of Health of the Russian Federation. Socially significant diseases of the Russian population in 2018 (statistical materials). M.; 2019. (In Russ.)
4. Lichterman L.B. Classification of cranial trauma. Sudebnaya meditsina. 2015; 1(3): 37-48. (In Russ.)
5. Saatman KE, Duhaime AC, Bullock R, Maas AIR, Valadka A, Manley GT, et al. Classification of traumatic brain injury for targeted therapies. J Neurotrauma. 2008; 25(7): 719-738. doi: 10.1089/neu.2008.0586
6. Schimmel SJ, Acosta S, Lozano D. Neuroinflammation intraumatic brain injury: A chronic response to an acute injury. Brain Circ. 2017; 3(3): 135-142. doi: 10.4103/bc.bc_18_17
7. Ladak AA, Enam SA, Ibrahim MT. A Review of the molecular mechanisms of traumatic brain injury. World Neurosurg. 2019; 131: 126-132. doi: 10.1016/j.wneu.2019.07.039
8. Sahel DK, Kaira M, Raj K, Sharma S, Singh S. Mitochondrial dysfunctioning and neuroinflammation: recent highlights on the possible mechanisms involved in traumatic brain injury. Neurosci Lett. 2019; 710: 134347. doi: 10.1016/j.neulet.2019.134347
9. Nasr IW, Chun Y, Kannan S. Neuroimmune responses in the developing brain following traumatic brain injury. Exp Neurol. 2019; 320: 112957. doi: 10.1016/j.expneurol.2019.112957
10. Needham EJ, Helmy A, Zanier ER, Jones JL, Coles AJ, Menon DK. The immunological response to traumatic brain injury. J Neuroimmunol. 2019; 332: 112-125. doi: 10.1016/j.jneuroim.2019.04.005
11. Pearn ML, Niesman IR, Egawa J, Sawada A, AlmenarQueralt A, Shah SB, et al. Pathophysiology associated with traumatic brain injury: current treatments and potential novel therapeutics. Cell Mol Neurobiol. 2017; 37(4): 571-585. doi: 10.1007/s10571-016-0400-1
12. Russo MV, McGavern DB. Inflammatory neuroprotection following traumatic brain injury. Science. 2016; 353(6301): 783-755. doi: 10.1126/science.aaf6260
13. Dinet V, Petry KG, Badaut J. Brain-immune interactions and neuroinflammation after traumatic brain injury. Front Neurosci. 2019; 13: 1178. doi: 10.3389/fnins.2019.01178
14. Casault C, Al Sultan AS, Banoei M, Couillard P, Kramer A, Winston BW. Cytokine responses in severe traumatic brain injury: where there is smoke, is there fire? Neurocrit Care. 2019; 30(1): 22-32. doi: 10.1007/s12028-018-0522-z
15. Rodney T, Osier N, Gill J. Pro- and anti-inflammatory biomarkers and traumatic brain injury outcomes: A review. Cytokine. 2018; 110: 248-256. doi: 10.1016/j.cyto.2018.01.012
16. Bogoslovsky T, Gill J, Jeromin A, Davis C, Diaz-Arrastia R. Fluid biomarkers of traumatic brain injury and intended context of use. Diagnostics (Basel). 2016; 6(4): 37. doi: 10.3390/diagnostics6040037
17. Yang DB, Yu WH, Dong XQ, Zhang ZY, Du Q, Zhu Q, et al. Serum macrophage migration inhibitory factor concentrations correlate with prognosis of traumatic brain injury. Clin Chim Acta. 2017; 469: 99-104. doi: 10.1016/j.cca.2017.03.030
18. Feng MJ, Ning W Bin, Wang W, Lv ZH, Liu XB, Zhu Y, et al. Serum S100A12 as a prognostic biomarker of severe traumatic brain injury. Clin Chim Acta. 2018; 480: 84-91. doi: 10.1016/j.cca.2018.01.044
19. Di Battista AP, Rhind SG, Hutchison MG, Hassan S, Shiu MY, Inaba K, et al. Inflammatory cytokine and chemokine profiles are associated with patient outcome and the hyperadrenergic state following acute brain injury. J Neuroinflammation. 2016; 13: 40. doi: 10.1186/s12974-016-0500-3
20. Lagerstedt L, Egea-Guerrero JJ, Rodríguez-Rodríguez A, Bustamante A, Montaner J, El Rahal A, et al. Early measurement of interleukin-10 predicts the absence of CT scan lesions in mild traumatic brain injury. PLoS One. 2018; 13(2): e0193278. doi: 10.1371/journal.pone.0193278
21. Banoei MM, Casault C, Metwaly SM, Winston BW. Metabolomics and biomarker discovery in traumatic brain injury. J Neurotrauma. 2018; 35(16): 1831-1848. doi: 10.1089/neu.2017.5326
22. Anada RP, Wong KT, Jayapalan JJ, Hashim OH, Ganesan D. Panel of serum protein biomarkers to grade the severity of traumatic brain injury. Electrophoresis. 2018; 39(18): 2308-2315. doi: 10.1002/elps.201700407
23. Huie JR, Diaz-Arrastia R, Yue JK, Sorani MD, Puccio AM, Okonkwo DO, et al. Testing a multivariate proteomic panel for traumatic brain injury biomarker discovery: a TRACK-TBI pilot study. J Neurotrauma. 2019; 36(1): 100-110. doi: 10.1089/neu.2017.5449
24. Corrigan F, Mander KA, Leonard AV, Vink R. Neurogenic inflammation after traumatic brain injury and its potentiation of classical inflammation. J Neuroinflammation. 2016; 13(1): 264. doi: 10.1186/s12974-016-0738-9
25. Vink R, Gabrielian L, Thornton E. The role of substance P in secondary pathophysiology after traumatic brain injury. Front Neurol. 2017; 8: 304. doi: 10.3389/fneur.2017.00304
26. Jassam YN, Izzy S, Whalen M, McGavern DB, El Khoury J. Neuroimmunology of traumatic brain injury: time for a paradigm shift. Neuron. 2017; 95(6): 1246‐1265. doi: 10.1016/j.neuron.2017.07.010
Review
For citations:
Zudova A.I., Sukhorosova A.G., Solomatina L.V. Traumatic Brain Injury and Neuroinflammation: Review of the Main Biomarkers. Acta Biomedica Scientifica. 2020;5(5):60-67. (In Russ.) https://doi.org/10.29413/ABS.2020-5.5.8
Views:
887
Email this article 
